US Residents Only


About Zokinvy®

Zokinvy interrupts a key disease process in young people with progeria and processing-deficient progeroid laminopathies (PDPL), helping to block progerin and progerin-like proteins from building up and damaging cells

About progeria and PDPL

Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), and PDPL are chronic disorders caused by genetic mutations that make harmful proteins that build up in cells over time.

The buildup of these proteins leads to progressive premature aging and heart problems usually seen in much older people. Young people with progeria age at a rapid rate, 8 to 10 times faster than healthy people of the same age.

Image Amen, 21, Togo. Photo courtesy of The Progeria Research Foundation.

How ZOKINVY works

Zokinvy is the first and only treatment for progeria and PDPL that targets the cause and symptoms of progeria and PDPL. It interrupts a key step in the disease process, helping to block progerin and progerin-like proteins from building up and damaging cells.

  • Image

    Healthy cell

  • Image

    Progeria cells contain abnormal protein

  • Image

    Cells treated with Zokinvy block accumulation of abnormal protein

See the Results of ZOKINVY


Do not take ZOKINVY if you are taking:

  • a strong or moderate CYP3A inhibitor or inducer
  • midazolam
  • lovastatin, simvastatin, and atorvastatin

WHAT IS Zokinvy® (lonafarnib)?

ZOKINVY (zoh-KIN-vee) is a prescription medicine used to treat Hutchinson-Gilford Progeria Syndrome and some types of Progeroid Laminopathies known as processing-deficient Progeroid Laminopathies. These illnesses are caused when the body makes harmful proteins called progerin and progerin-like proteins.